177 Lu-FAP-2286 Therapy for Advanced Lung Adenocarcinoma With Multiple Metastases : A Promising Last-line Treatment Option.

A 62-year-old man was diagnosed with lung adenocarcinoma and metastases involving the bone, muscle, peritoneum, and lymph nodes. He received one cycle of 177 Lu-FAP-2286 therapy. One month after treatment, the clinical symptoms, including chest pain, shortness of breath, and productive cough, had completely resolved. Follow-up 68 Ga-FAP-2286 imaging at 2 months demonstrated partial metabolic response (PERCIST 1.0), accompanied by a marked reduction in respiratory tumor marker levels. In addition, no adverse reactions were reported by the patient.